Immunovant (IMVT) Treasury Shares (2020 - 2026)

Immunovant has reported Treasury Shares for 7 years, with the latest figure at $3.5 million in Q1 2026.

• For the quarter ending Q1 2026, Treasury Shares rose 7.57% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at $3.5 million (up 7.57% YoY), and the FY2026 full-year result was $3.5 million, up 7.57% from the prior year.
• Treasury Shares for Q1 2026 stood at $3.5 million, down from $3.9 million in the prior quarter.
• The five-year high for Treasury Shares was $5.0 million in Q2 2023, with the low at $2.7 million in Q1 2022.
• Historically, Treasury Shares has averaged $3.8 million across 5 years, with a median of $3.8 million in 2023.
• Annual changes were most pronounced in 2022 — Treasury Shares jumped 193.11% — and 2024, when it fell 20.02%.
• Immunovant's Treasury Shares stood at $4.5 million in 2022, then dropped by 16.47% to $3.8 million in 2023, then retreated by 6.48% to $3.5 million in 2024, then advanced by 9.81% to $3.9 million in 2025, then retreated by 10.29% to $3.5 million in 2026.
• The last three Treasury Shares figures came in at $3.5 million (Q1 2026), $3.9 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.